JP2019068857A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019068857A5 JP2019068857A5 JP2019019707A JP2019019707A JP2019068857A5 JP 2019068857 A5 JP2019068857 A5 JP 2019068857A5 JP 2019019707 A JP2019019707 A JP 2019019707A JP 2019019707 A JP2019019707 A JP 2019019707A JP 2019068857 A5 JP2019068857 A5 JP 2019068857A5
- Authority
- JP
- Japan
- Prior art keywords
- human
- microglobulin
- acid sequence
- nucleic acid
- human animal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 29
- 150000007523 nucleic acids Chemical group 0.000 claims 29
- 108010081355 beta 2-Microglobulin Proteins 0.000 claims 19
- 102000015736 beta 2-Microglobulin Human genes 0.000 claims 16
- 101000937544 Homo sapiens Beta-2-microglobulin Proteins 0.000 claims 14
- 229920001184 polypeptide Polymers 0.000 claims 12
- 102000004196 processed proteins & peptides Human genes 0.000 claims 12
- 108090000765 processed proteins & peptides Proteins 0.000 claims 12
- 210000004027 cell Anatomy 0.000 claims 11
- 101000937526 Mus musculus Beta-2-microglobulin Proteins 0.000 claims 8
- 102000047279 human B2M Human genes 0.000 claims 7
- 238000000034 method Methods 0.000 claims 7
- 230000001105 regulatory effect Effects 0.000 claims 6
- 108700024394 Exon Proteins 0.000 claims 4
- 241000283984 Rodentia Species 0.000 claims 3
- 150000001413 amino acids Chemical class 0.000 claims 3
- 101000729860 Rattus norvegicus Beta-2-microglobulin Proteins 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 210000001161 mammalian embryo Anatomy 0.000 claims 1
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161552582P | 2011-10-28 | 2011-10-28 | |
| US201161552587P | 2011-10-28 | 2011-10-28 | |
| US61/552,582 | 2011-10-28 | ||
| US61/552,587 | 2011-10-28 | ||
| US201261700908P | 2012-09-14 | 2012-09-14 | |
| US61/700,908 | 2012-09-14 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017109327A Division JP6574457B2 (ja) | 2011-10-28 | 2017-06-01 | 遺伝子改変された主要組織適合複合体マウス |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020081774A Division JP2020146041A (ja) | 2011-10-28 | 2020-05-07 | 遺伝子改変された主要組織適合複合体マウス |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019068857A JP2019068857A (ja) | 2019-05-09 |
| JP2019068857A5 true JP2019068857A5 (OSRAM) | 2019-12-19 |
| JP6866409B2 JP6866409B2 (ja) | 2021-04-28 |
Family
ID=47178940
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014539029A Active JP6154391B2 (ja) | 2011-10-28 | 2012-10-26 | 遺伝子改変された主要組織適合複合体マウス |
| JP2017109327A Active JP6574457B2 (ja) | 2011-10-28 | 2017-06-01 | 遺伝子改変された主要組織適合複合体マウス |
| JP2019019707A Active JP6866409B2 (ja) | 2011-10-28 | 2019-02-06 | 遺伝子改変された主要組織適合複合体マウス |
| JP2020081774A Withdrawn JP2020146041A (ja) | 2011-10-28 | 2020-05-07 | 遺伝子改変された主要組織適合複合体マウス |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014539029A Active JP6154391B2 (ja) | 2011-10-28 | 2012-10-26 | 遺伝子改変された主要組織適合複合体マウス |
| JP2017109327A Active JP6574457B2 (ja) | 2011-10-28 | 2017-06-01 | 遺伝子改変された主要組織適合複合体マウス |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020081774A Withdrawn JP2020146041A (ja) | 2011-10-28 | 2020-05-07 | 遺伝子改変された主要組織適合複合体マウス |
Country Status (27)
| Country | Link |
|---|---|
| US (3) | US9615550B2 (OSRAM) |
| EP (4) | EP3262932B1 (OSRAM) |
| JP (4) | JP6154391B2 (OSRAM) |
| KR (3) | KR102295746B1 (OSRAM) |
| CN (3) | CN104039132B9 (OSRAM) |
| AU (3) | AU2012324016C1 (OSRAM) |
| BR (1) | BR112014009259A2 (OSRAM) |
| CA (2) | CA2850387A1 (OSRAM) |
| CY (2) | CY1119657T1 (OSRAM) |
| DK (2) | DK2770821T3 (OSRAM) |
| ES (3) | ES2962287T3 (OSRAM) |
| HK (1) | HK1249712B (OSRAM) |
| HR (2) | HRP20171761T1 (OSRAM) |
| HU (2) | HUE035652T2 (OSRAM) |
| IL (3) | IL232097A (OSRAM) |
| LT (2) | LT3262932T (OSRAM) |
| MX (3) | MX376167B (OSRAM) |
| MY (2) | MY178723A (OSRAM) |
| NZ (1) | NZ734532A (OSRAM) |
| PL (2) | PL3262932T3 (OSRAM) |
| PT (2) | PT2770821T (OSRAM) |
| RS (2) | RS56656B1 (OSRAM) |
| SG (2) | SG10201603188SA (OSRAM) |
| SI (2) | SI3262932T1 (OSRAM) |
| SM (2) | SMT201900478T1 (OSRAM) |
| WO (1) | WO2013063346A1 (OSRAM) |
| ZA (1) | ZA201403085B (OSRAM) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112014008529A2 (pt) | 2011-10-28 | 2017-04-18 | Regeneron Pharma | il-6 humanizado e receptor de il-6 |
| US9591835B2 (en) | 2011-10-28 | 2017-03-14 | Regeneron Pharmaceuticals, Inc. | Genetically modified major histocompatibility complex animals |
| EP3543253B1 (en) | 2013-02-20 | 2024-03-27 | Regeneron Pharmaceuticals, Inc. | Mice expressing humanized t-cell co-receptors |
| US20150342163A1 (en) | 2013-02-22 | 2015-12-03 | Regeneron Pharmaceuticals, Inc. | Genetically modified major histocompatibility complex mice |
| HRP20181866T1 (hr) | 2013-02-22 | 2019-01-25 | Regeneron Pharmaceuticals, Inc. | Miševi koji izražavaju humanizirane komplekse glavne histokompatibilnosti |
| CA2902543A1 (en) * | 2013-03-11 | 2014-10-09 | Regeneron Pharmaceuticals, Inc. | Transgenic mice expressing chimeric major histocompatibility complex (mhc) class i molecules |
| KR102407354B1 (ko) | 2013-09-23 | 2022-06-10 | 리제너론 파마슈티칼스 인코포레이티드 | 인간화된 신호-조절 단백질 유전자를 가지는 비-인간 동물 |
| SI3138397T1 (sl) | 2013-10-15 | 2019-04-30 | Regeneron Pharmaceuticals, Inc. | Humanizirane živali IL-15 |
| US10278373B2 (en) | 2013-10-18 | 2019-05-07 | Taiho Pharmaceutical Co., Ltd. | HLA class I-expressing non-human animal |
| US20150143558A1 (en) | 2013-11-19 | 2015-05-21 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a humanized b-cell activating factor gene |
| MX358206B (es) | 2013-11-19 | 2018-08-09 | Regeneron Pharma | Animales no humanos que tienen un gen humanizado de un ligando inductor de la proliferacion. |
| DK3129400T3 (da) | 2014-04-08 | 2020-06-08 | Regeneron Pharma | Ikke-humane dyr med humaniserede Fc-gamma-receptorer |
| US9795121B2 (en) | 2014-05-05 | 2017-10-24 | Regeneron Pharmaceuticals, Inc. | Humanized C3 animals |
| NO2785538T3 (OSRAM) | 2014-05-07 | 2018-08-04 | ||
| SMT202000184T1 (it) | 2014-06-19 | 2020-05-08 | Regeneron Pharma | Animali non umani aventi un gene 1 della morte cellulare programmata umanizzato |
| AU2015317370A1 (en) | 2014-09-19 | 2017-03-23 | Regeneron Pharmaceuticals, Inc. | Chimeric antigen receptors |
| EP3223605B9 (en) | 2014-11-24 | 2021-08-18 | Regeneron Pharmaceuticals, Inc. | Non-human animals expressing humanized cd3 complex |
| HUE064960T2 (hu) | 2014-12-05 | 2024-04-28 | Regeneron Pharma | Differenciációs 47 gén humanizált klasztert tartalmazó nem-humán állatok |
| AU2015360667B2 (en) * | 2014-12-09 | 2021-09-23 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a humanized cluster of differentiation 274 gene |
| KR102656470B1 (ko) * | 2014-12-10 | 2024-04-09 | 리전츠 오브 더 유니버스티 오브 미네소타 | 질환을 치료하기 위한 유전적으로 변형된 세포, 조직 및 장기 |
| WO2016164492A2 (en) | 2015-04-06 | 2016-10-13 | Regeneron Pharmaceuticals, Inc. | Humanized t cell mediated immune responses in non-human animals |
| CN107896479B (zh) * | 2015-04-13 | 2021-07-13 | 再生元制药公司 | 人源化SIRPα-IL15敲入小鼠及其使用方法 |
| EP3376857B1 (en) | 2015-11-20 | 2021-02-24 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a humanized lymphocyte-activation gene 3 |
| PT3422845T (pt) | 2016-02-29 | 2021-08-26 | Regeneron Pharma | Roedores com um gene tmprss humanizado |
| KR102784608B1 (ko) | 2016-06-03 | 2025-03-27 | 리제너론 파마슈티칼스 인코포레이티드 | 외인성 말단 데옥시뉴클레오타이드 전달효소를 발현하는 비인간 동물 |
| CN109456942A (zh) * | 2017-09-06 | 2019-03-12 | 亘喜生物科技（上海）有限公司 | 通用型嵌合抗原受体t细胞制备技术 |
| EP4276185A3 (en) | 2017-09-29 | 2024-02-21 | Regeneron Pharmaceuticals, Inc. | Rodents comprising a humanized ttr locus and methods of use |
| DK3687287T5 (da) * | 2017-09-29 | 2024-08-26 | Regeneron Pharma | Gnavere, udtrykkende humaniseret c1q-kompleks |
| CN111655031B (zh) | 2017-11-30 | 2022-11-18 | 瑞泽恩制药公司 | 包含人源化trkb基因座的非人动物 |
| SMT202500038T1 (it) | 2018-03-24 | 2025-03-12 | Regeneron Pharma | Topi o ratti geneticamente modificati per la generazione di anticorpi terapeutici contro complessi peptide-mhc, metodi di produzione e loro utilizzo |
| IL314733A (en) | 2018-03-26 | 2024-10-01 | Regeneron Pharma | Humanized rodents for testing therapeutic agents |
| US11589562B2 (en) | 2018-07-16 | 2023-02-28 | Regeneran Pharmaceuticals, Inc. | Mouse model of DITRA disease and uses thereof |
| US10883084B2 (en) | 2018-10-05 | 2021-01-05 | Xenotherapeutics, Inc. | Personalized cells, tissues, and organs for transplantation from a humanized, bespoke, designated-pathogen free, (non-human) donor and methods and products relating to same |
| EP3945799A1 (en) * | 2019-03-25 | 2022-02-09 | Xenotherapeutics, Inc. | Personalized cells, tissues, and organs for transplantation from a humanized, bespoke, designated-pathogen free, (non- human) donor and methods and products relating to same |
| IL286905B2 (en) | 2019-04-04 | 2024-06-01 | Regeneron Pharma | Non-human animals containing the human coagulation factor 12 locus |
| KR20220016869A (ko) | 2019-06-04 | 2022-02-10 | 리제너론 파마슈티칼스 인코포레이티드 | 베타-슬립 돌연변이를 갖는 인간화 ttr 좌위를 포함하는 비-인간 동물 및 사용 방법 |
| BR112021022722A2 (pt) | 2019-06-07 | 2022-01-04 | Regeneron Pharma | Animal não humano, célula de animal não humana, genoma de animal não humano, gene de albumina animal não humana humanizada, vetor de alvejamento, método de avaliação da atividade de um reagente, e, método de otimização da atividade de um reagente |
| JP7600245B2 (ja) * | 2020-01-10 | 2024-12-16 | バイオサイトジェン ファーマシューティカルズ （ベイジン） カンパニー リミテッド | ヒト又はキメラｍｈｃタンパク質複合体を有する遺伝子組換え非ヒト動物 |
| WO2022133155A1 (en) * | 2020-12-16 | 2022-06-23 | Xenotherapeutics, Inc. | Humanization of beta2-microglobulin in porcine genome resulting in functional expression of human βeta2-microglobulin within donor cells, tissues, or organs |
| CA3199879A1 (en) | 2020-12-16 | 2022-06-23 | Regeneron Pharmaceuticals, Inc. | Mice expressing humanized fc alpha receptors |
| CN118511853A (zh) | 2021-03-31 | 2024-08-20 | 瑞泽恩制药公司 | 包含具有改善的tcrb组库多样性的人源化细胞免疫系统组分的基因修饰的小鼠 |
| JP2025519477A (ja) | 2022-06-07 | 2025-06-26 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ｔ細胞活性を調節するための多重特異性分子及びその使用 |
| WO2023240124A1 (en) | 2022-06-07 | 2023-12-14 | Regeneron Pharmaceuticals, Inc. | Pseudotyped viral particles for targeting tcr-expressing cells |
| WO2024064860A1 (en) | 2022-09-22 | 2024-03-28 | Regeneron Pharmaceuticals, Inc. | Genetically modified mice expressing components of human cellular immune system |
| KR20250160369A (ko) | 2023-01-27 | 2025-11-12 | 리제너론 파마슈티칼스 인코포레이티드 | 변형된 랩도바이러스 당단백질 및 이의 용도 |
| TW202520975A (zh) * | 2023-08-09 | 2025-06-01 | 英商劍橋企業有限公司 | 基因改造之囓齒動物及囓齒動物細胞以及其等用途 |
| WO2025064470A1 (en) | 2023-09-19 | 2025-03-27 | Regeneron Pharmaceuticals, Inc. | Viral peptides and uses thereof |
| WO2025064761A1 (en) | 2023-09-22 | 2025-03-27 | Regeneron Pharmaceuticals, Inc. | Kras10-18 g12d off-target peptides and uses thereof |
| WO2025064738A1 (en) | 2023-09-22 | 2025-03-27 | Regeneron Pharmaceuticals, Inc. | Dntt 250-258 off-target peptides and uses thereof |
| WO2025136809A2 (en) | 2023-12-19 | 2025-06-26 | Regeneron Pharmaceuticals, Inc. | Foxp3 peptides and uses thereof |
| WO2025178991A1 (en) | 2024-02-21 | 2025-08-28 | Regeneron Pharmaceuticals, Inc. | Splicing factor gene mutation-associated neoantigenic peptides and uses thereof |
| WO2025212991A1 (en) | 2024-04-05 | 2025-10-09 | Regeneron Pharmaceuticals, Inc. | Rodent models of disease |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5413923A (en) | 1989-07-25 | 1995-05-09 | Cell Genesys, Inc. | Homologous recombination for universal donor cells and chimeric mammalian hosts |
| DE69034263D1 (de) | 1989-07-25 | 2009-04-02 | Cell Genesys Inc | Homologe Rekombination für universelle Donorzellen und chimerische Säugetierzellen |
| US5574205A (en) | 1989-07-25 | 1996-11-12 | Cell Genesys | Homologous recombination for universal donor cells and chimeric mammalian hosts |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| GB9100481D0 (en) | 1991-01-10 | 1991-02-20 | Inst Nat Sante Rech Med | Genetically engineered mice |
| AU2661692A (en) | 1991-09-19 | 1993-04-27 | President And Fellows Of Harvard College | Transgenic mhc class i and class ii antigen-deficient mammals |
| EP0663952A4 (en) | 1992-09-11 | 1997-06-11 | Univ California | Transgenic non-human animals having targeted lymphocyte transduction genes. |
| US5523226A (en) | 1993-05-14 | 1996-06-04 | Biotechnology Research And Development Corp. | Transgenic swine compositions and methods |
| GB9315303D0 (en) | 1993-07-23 | 1993-09-08 | Zeneca Ltd | Polypeptide |
| US5965787A (en) | 1995-08-31 | 1999-10-12 | Mayo Foundation For Medical Education And Research | HLA-DRBI peptides with specific binding affinity for HLA-DQ molecules: prevention and treatment of rheumatoid arthritis |
| US6002066A (en) | 1996-01-16 | 1999-12-14 | Ortho Pharmaceutical Corp. | H2-M modified transgenic mice |
| WO1997032603A1 (en) | 1996-03-05 | 1997-09-12 | The Scripps Research Institute | Recombinant constructs encoding t cell receptors specific for human hla-restricted tumor antigens |
| ES2301183T3 (es) | 1996-12-03 | 2008-06-16 | Amgen Fremont Inc. | Anticuerpo completamente humano que se une al receptor del egfr. |
| PT1017721E (pt) | 1997-09-16 | 2009-05-07 | Univ Oregon Health & Science | Moléculas de mhc recombinantes úteis para manipulação de células t específicas do antigénio |
| US6372955B1 (en) | 1998-02-17 | 2002-04-16 | Ortho Mcneil Pharmaceutical, Inc. | Methods for Producing B cells and antibodies from H2-O modified transgenic mice |
| DE69917541T2 (de) * | 1998-02-17 | 2005-06-02 | Ortho-Mcneil Pharmaceutical, Inc. | H2-o modifizierte transgene tiere |
| AU1023401A (en) * | 1999-10-12 | 2001-04-23 | Institut Pasteur | Design of a polyepitopic construct for the induction of hla-a2.1 restricted hiv 1 specific ctl responses using hhd mice |
| US7105348B2 (en) | 2000-10-31 | 2006-09-12 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US6586251B2 (en) | 2000-10-31 | 2003-07-01 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US20050050580A1 (en) | 2000-12-13 | 2005-03-03 | Masashi Gotoh | Transgenic animal expressing hla-a24 and utilization thereof |
| DK1409646T3 (da) * | 2000-12-19 | 2012-08-06 | Altor Bioscience Corp | Transgene dyr omfattende et humaniseret immunsystem |
| FR2827302B1 (fr) * | 2001-07-13 | 2003-10-10 | Genoway | Cellule et animal transgenique modelisant la presentation antigenique humaine et leurs utilisations |
| US8895020B2 (en) | 2002-04-19 | 2014-11-25 | Washington University | Single chain trimers and uses therefor |
| US7179645B2 (en) * | 2002-09-24 | 2007-02-20 | Antigen Express, Inc. | Ii-Key/antigenic epitope hybrid peptide vaccines |
| US7663017B2 (en) | 2003-07-30 | 2010-02-16 | Institut Pasteur | Transgenic mice having a human major histocompatability complex (MHC) phenotype, experimental uses and applications |
| JP4857450B2 (ja) | 2004-03-09 | 2012-01-18 | 財団法人名古屋産業科学研究所 | ヒト関節リウマチの病態を再現するトランスジェニック非ヒト哺乳動物 |
| DK1802193T3 (da) | 2004-10-19 | 2014-06-10 | Regeneron Pharma | Fremgangsmåde til frembringelse af en homozygot mus til genetisk modifikation |
| JP4830139B2 (ja) * | 2006-03-10 | 2011-12-07 | 学校法人明治大学 | クローン胚の作製方法 |
| NZ547859A (en) * | 2006-06-09 | 2009-05-31 | Dec Int Nz Ltd | Treatment method and composition for mastitis |
| EP1878342A1 (en) * | 2006-07-13 | 2008-01-16 | Institut Pasteur | Immunodeficient mice transgenic for HLA class I and HLA class II molecules and their uses |
| EP1878798A1 (en) | 2006-07-13 | 2008-01-16 | Institut Pasteur | Method of producing a multichimeric mouse and applications to study the immunopathogenesis of human tissue-specific pathologies |
| JP2010526066A (ja) * | 2007-04-23 | 2010-07-29 | シェーリング コーポレイション | 抗ｍｄｌ−１抗体 |
| US20090271884A1 (en) | 2008-03-07 | 2009-10-29 | Regeneron Pharmaceuticals, Inc. | ES Cell-Derived Mice From Diploid Host Embryo Injection |
| US20090328240A1 (en) | 2008-06-24 | 2009-12-31 | Sing George L | Genetically modified mice as predictors of immune response |
| EP2153845A1 (en) * | 2008-08-13 | 2010-02-17 | Julius-Maximilians-Universität Würzburg | Endoglin peptides, vaccines and methods for preparing the same |
| EP2564695B1 (en) | 2009-07-08 | 2015-04-15 | Kymab Limited | Animal models and therapeutic molecules |
| US9557323B2 (en) | 2010-09-24 | 2017-01-31 | The United States Of America As Represented By The Secretary Of The Navy | Humanized transgenic mouse model |
| EP3543253B1 (en) | 2013-02-20 | 2024-03-27 | Regeneron Pharmaceuticals, Inc. | Mice expressing humanized t-cell co-receptors |
| HRP20181866T1 (hr) | 2013-02-22 | 2019-01-25 | Regeneron Pharmaceuticals, Inc. | Miševi koji izražavaju humanizirane komplekse glavne histokompatibilnosti |
| US20150342163A1 (en) | 2013-02-22 | 2015-12-03 | Regeneron Pharmaceuticals, Inc. | Genetically modified major histocompatibility complex mice |
| SG11201509743WA (en) * | 2013-06-03 | 2015-12-30 | Theravectys | Lentiviral vectors containing an mhc class i, mhc class ii, or beta-2 microglobulin upstream promoter sequence |
| US10278373B2 (en) * | 2013-10-18 | 2019-05-07 | Taiho Pharmaceutical Co., Ltd. | HLA class I-expressing non-human animal |
| WO2016164492A2 (en) | 2015-04-06 | 2016-10-13 | Regeneron Pharmaceuticals, Inc. | Humanized t cell mediated immune responses in non-human animals |
-
2012
- 2012-10-26 DK DK12787255.4T patent/DK2770821T3/da active
- 2012-10-26 PL PL17184955T patent/PL3262932T3/pl unknown
- 2012-10-26 WO PCT/US2012/062042 patent/WO2013063346A1/en not_active Ceased
- 2012-10-26 KR KR1020207002887A patent/KR102295746B1/ko active Active
- 2012-10-26 JP JP2014539029A patent/JP6154391B2/ja active Active
- 2012-10-26 CA CA2850387A patent/CA2850387A1/en active Pending
- 2012-10-26 BR BR112014009259-1A patent/BR112014009259A2/pt not_active Application Discontinuation
- 2012-10-26 ES ES19167619T patent/ES2962287T3/es active Active
- 2012-10-26 SI SI201231650T patent/SI3262932T1/sl unknown
- 2012-10-26 RS RS20171195A patent/RS56656B1/sr unknown
- 2012-10-26 SM SM20190478T patent/SMT201900478T1/it unknown
- 2012-10-26 CA CA3074400A patent/CA3074400C/en active Active
- 2012-10-26 PT PT127872554T patent/PT2770821T/pt unknown
- 2012-10-26 CN CN201280060540.8A patent/CN104039132B9/zh active Active
- 2012-10-26 EP EP17184955.7A patent/EP3262932B1/en active Active
- 2012-10-26 HU HUE12787255A patent/HUE035652T2/en unknown
- 2012-10-26 CN CN202110831383.7A patent/CN113564188B/zh active Active
- 2012-10-26 KR KR1020147014476A patent/KR101921126B1/ko active Active
- 2012-10-26 SG SG10201603188SA patent/SG10201603188SA/en unknown
- 2012-10-26 MX MX2017013466A patent/MX376167B/es unknown
- 2012-10-26 HU HUE17184955A patent/HUE045879T2/hu unknown
- 2012-10-26 CN CN201710347715.8A patent/CN107254480B/zh active Active
- 2012-10-26 ES ES17184955T patent/ES2741649T3/es active Active
- 2012-10-26 PL PL12787255T patent/PL2770821T3/pl unknown
- 2012-10-26 NZ NZ734532A patent/NZ734532A/en unknown
- 2012-10-26 SI SI201231136T patent/SI2770821T1/en unknown
- 2012-10-26 US US13/661,159 patent/US9615550B2/en active Active
- 2012-10-26 PT PT17184955T patent/PT3262932T/pt unknown
- 2012-10-26 HR HRP20171761TT patent/HRP20171761T1/hr unknown
- 2012-10-26 LT LTEP17184955.7T patent/LT3262932T/lt unknown
- 2012-10-26 EP EP12787255.4A patent/EP2770821B1/en active Active
- 2012-10-26 MX MX2020010763A patent/MX391222B/es unknown
- 2012-10-26 AU AU2012324016A patent/AU2012324016C1/en active Active
- 2012-10-26 MY MYPI2017703836A patent/MY178723A/en unknown
- 2012-10-26 MX MX2014004895A patent/MX355725B/es active IP Right Grant
- 2012-10-26 DK DK17184955.7T patent/DK3262932T3/da active
- 2012-10-26 KR KR1020187033187A patent/KR102074145B1/ko active Active
- 2012-10-26 SM SM20170576T patent/SMT201700576T1/it unknown
- 2012-10-26 RS RS20190998A patent/RS59082B1/sr unknown
- 2012-10-26 ES ES12787255.4T patent/ES2651517T3/es active Active
- 2012-10-26 LT LTEP12787255.4T patent/LT2770821T/lt unknown
- 2012-10-26 EP EP19167619.6A patent/EP3563680B1/en active Active
- 2012-10-26 SG SG11201400933VA patent/SG11201400933VA/en unknown
- 2012-10-26 MY MYPI2014000784A patent/MY164836A/en unknown
- 2012-10-26 EP EP23193595.8A patent/EP4311833A3/en active Pending
-
2014
- 2014-04-13 IL IL232097A patent/IL232097A/en active IP Right Grant
- 2014-04-25 ZA ZA2014/03085A patent/ZA201403085B/en unknown
-
2016
- 2016-04-27 AU AU2016202688A patent/AU2016202688B2/en active Active
-
2017
- 2017-02-22 US US15/439,828 patent/US10869466B2/en active Active
- 2017-04-30 IL IL252022A patent/IL252022A0/en active IP Right Grant
- 2017-06-01 JP JP2017109327A patent/JP6574457B2/ja active Active
- 2017-11-22 CY CY20171101223T patent/CY1119657T1/el unknown
- 2017-12-22 AU AU2017279797A patent/AU2017279797C1/en active Active
-
2018
- 2018-06-29 HK HK18108466.8A patent/HK1249712B/en unknown
- 2018-08-20 IL IL26123918A patent/IL261239B/en active IP Right Grant
-
2019
- 2019-02-06 JP JP2019019707A patent/JP6866409B2/ja active Active
- 2019-08-06 HR HRP20191420 patent/HRP20191420T1/hr unknown
- 2019-08-07 CY CY20191100840T patent/CY1121869T1/el unknown
-
2020
- 2020-05-07 JP JP2020081774A patent/JP2020146041A/ja not_active Withdrawn
- 2020-08-12 US US16/991,283 patent/US20200375160A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019068857A5 (OSRAM) | ||
| Ristevski | Making better transgenic models: conditional, temporal, and spatial approaches | |
| JP2017505127A5 (OSRAM) | ||
| Zhang et al. | Inactivation of the myogenic bHLH gene MRF4 results in up-regulation of myogenin and rib anomalies. | |
| Knapp et al. | Loss of myogenin in postnatal life leads to normal skeletal muscle but reduced body size | |
| US10385359B2 (en) | Targeted modification of rat genome | |
| Spear et al. | Transcriptional control in the mammalian liver: liver development, perinatal repression, and zonal gene regulation | |
| Doetschman et al. | Cardiac-specific inducible and conditional gene targeting in mice | |
| Miao et al. | Translation repression by maternal RNA binding protein Zar1 is essential for early oogenesis in zebrafish | |
| JP2017514496A5 (OSRAM) | ||
| RU2016123708A (ru) | Отличные от человека животные, содержащие гуманизированный ген фактора активации в-клеток | |
| HRP20202034T1 (hr) | Neljudske životinje s genom za humanizirani diferencijacijski biljeg cd274 | |
| WO2015077072A4 (en) | Non-human animals having a humanized a proliferation-inducing ligand gene | |
| DK0620849T3 (da) | Transgene dyremodeller for Alzheimer's sygdom | |
| Li et al. | A transgenic zebrafish model for monitoring xbp1 splicing and endoplasmic reticulum stress in vivo | |
| Oura et al. | KCTD19 and its associated protein ZFP541 are independently essential for meiosis in male mice | |
| JP2019506897A5 (OSRAM) | ||
| Hernández-Morán et al. | Degron tagging for rapid protein degradation in mice | |
| RU2676961C2 (ru) | Грызуны с условными мутантными аллелями acvr1 | |
| Kato et al. | Regulation of doublesex1 expression for environmental sex determination in the cladoceran crustacean Daphnia | |
| JP2021526815A (ja) | 進行性骨化性線維異形成症のげっ歯類モデル | |
| JP2008501357A5 (OSRAM) | ||
| Jin et al. | The alpha-fetoprotein enhancer region activates the albumin and alpha-fetoprotein promoters during liver development | |
| WO2017175745A1 (ja) | 生殖細胞欠損動物を用いる遺伝子改変動物の作製方法 | |
| Pohlkamp et al. | Generation and characterization of an Nse-CreERT2 transgenic line suitable for inducible gene manipulation in cerebellar granule cells |